Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.

AACR 2018

14 - 18 Apr 2018

McCormick Place North/South, Chicago, United States of America

Dose escalation of durvalumab with tremelimumab for metastatic urothelial cancer

Dr Arjun Balar - NYU Langone Medical Center, New York, USA

Dose escalation of durvalumab with tremelimumab for metastatic urothelial cancer ( Dr Arjun Balar - NYU Langone Medical Center, New York, USA )

Developing off-the-shelf CAR T cells with stem cell libraries

Dr Bob Velamehr - Fate Therapeutics, La Jolla, USA

Developing off-the-shelf CAR T cells with stem cell libraries ( Dr Bob Velamehr - Fate Therapeutics, La Jolla, USA )

Neoadjuvant nivolumab for resectable lung cancer

Dr Drew Pardoll - Johns Hopkins Medicine, Baltimore, USA

Neoadjuvant nivolumab for resectable lung cancer ( Dr Drew Pardoll - Johns Hopkins Medicine, Baltimore, USA )

Biomarkers of pembrolizumab response in head and neck cancer

Dr Tanguy Seiwert - The University of Chicago Medicine, Chicago, USA

Biomarkers of pembrolizumab response in head and neck cancer ( Dr Tanguy Seiwert - The University of Chicago Medicine, Chicago, USA )

Phase I taselisib results and a cell-free DNA assay

Dr José Baselga - Memorial Sloan Kettering Cancer Center, New York, USA

Phase I taselisib results and a cell-free DNA assay ( Dr José Baselga - Memorial Sloan Kettering Cancer Center, New York, USA )

Safety indications in mouse models treated with full doses of MEK inhibitors and SHP099

Dr Carmine Fedele - Laura and Isaac Perlmutter Cancer Center at New York University Langone Medical, New York, USA

Safety indications in mouse models treated with full doses of MEK inhibitors and SHP099 ( Dr Carmine Fedele - Laura and Isaac Perlmutter Cancer Center at New York University Langone Medical, New York, USA )

A variety of approaches to measure the efficacy of PARP inhibitors

Dr Elisabetta Leo - AstraZeneca, Cambridge, UK

A variety of approaches to measure the efficacy of PARP inhibitors ( Dr Elisabetta Leo - AstraZeneca, Cambridge, UK )

Development and clinical indications of PARP inhibitors

Dr Mark O'Connor - AstraZeneca, Cambridge, UK

Development and clinical indications of PARP inhibitors ( Dr Mark O'Connor - AstraZeneca, Cambridge, UK )

Mechanisms and prospects of a novel CDK9 inhibitor for DLBCL

Dr Susan Galbraith - AstraZeneca, Cambridge, UK

Mechanisms and prospects of a novel CDK9 inhibitor for DLBCL ( Dr Susan Galbraith - AstraZeneca, Cambridge, UK )

Front-line therapy of DIPG using IDO inhibitor with radiation and chemotherapy

Dr Theodore Johnson - Georgia Cancer Center, Augusta, USA

Front-line therapy of DIPG using IDO inhibitor with radiation and chemotherapy ( Dr Theodore Johnson - Georgia Cancer Center, Augusta, USA )

Impact of microbiome on head and neck cancers

Dr Young Jun Kim - Vanderbilt-Ingram Cancer Center, Nashville, USA

Impact of microbiome on head and neck cancers ( Dr Young Jun Kim - Vanderbilt-Ingram Cancer Center, Nashville, USA )

First-in-human trial results of RET targeted BLU-667

Prof Vivek Subbiah - MD Anderson Cancer Center, Houston, USA

First-in-human trial results of RET targeted BLU-667 ( Prof Vivek Subbiah - MD Anderson Cancer Center, Houston, USA )

Treating RET alterations with novel therapy BLU-667

Prof Vivek Subbiah - MD Anderson Cancer Center, Houston, USA

Treating RET alterations with novel therapy BLU-667 ( Prof Vivek Subbiah - MD Anderson Cancer Center, Houston, USA )

AKT inhibitors in research and application

Dr Brian Schwartz - ArQule, Burlington, USA

AKT inhibitors in research and application ( Dr Brian Schwartz - ArQule, Burlington, USA )

Tandem duplications in triple negative breast cancer

Dr Ed Liu - The Jackson Laboratory, Bar Harbor, USA

Tandem duplications in triple negative breast cancer ( Dr Ed Liu - The Jackson Laboratory, Bar Harbor, USA )

Increasing diversity through the NCI SBIR development centre

Dr Christie Canaria - National Cancer Institute, Rockville, USA

Increasing diversity through the NCI SBIR development centre ( Dr Christie Canaria - National Cancer Institute, Rockville, USA )

The importance of online patient groups and 'The ROS1ders'

Janet Freeman-Daily - The ROS1ders

The importance of online patient groups and 'The ROS1ders' ( Janet Freeman-Daily - The ROS1ders )

Effects of dasatinib on xenograft lung tumour models with YES1 overexpression

Dr Irati Garmendia - University of Navarra, Pamplona, Spain

Effects of dasatinib on xenograft lung tumour models with YES1 overexpression ( Dr Irati Garmendia - University of Navarra, Pamplona, Spain )

Analysis tools for NCI genomic databases

Dr Jean Claude Zenklusen - National Cancer Institute, Rockville, USA

Analysis tools for NCI genomic databases ( Dr Jean Claude Zenklusen - National Cancer Institute, Rockville, USA )

Results from GOBACK: Non-chromosomal birth defects linked with cancer

Dr Jeremy Schraw - Baylor College of Medicine, Houston, USA

Results from GOBACK: Non-chromosomal birth defects linked with cancer ( Dr Jeremy Schraw - Baylor College of Medicine, Houston, USA )

A link between non-chromosomal birth defects and cancer

Dr Jeremy Schraw - Baylor College of Medicine, Houston, USA

A link between non-chromosomal birth defects and cancer ( Dr Jeremy Schraw - Baylor College of Medicine, Houston, USA )

Novel gene biomarkers in multiple cancers derived from non-malignant breast phenotypes

Jon Obenauer - Rancho BioSciences, Rancho Santa Fe, USA

Novel gene biomarkers in multiple cancers derived from non-malignant breast phenotypes ( Jon Obenauer - Rancho BioSciences, Rancho Santa Fe, USA )

Reducing recurrence of advanced melanoma with pembrolizumab

Prof Alex Eggermont - Paris-Sud University, Paris, France

Reducing recurrence of advanced melanoma with pembrolizumab ( Prof Alex Eggermont - Paris-Sud University, Paris, France )

Results of KEYNOTE-054; melanoma patients treated with pembrolizumab.

Prof Alex Eggermont - Paris-Sud University, Paris, France

Results of KEYNOTE-054; melanoma patients treated with pembrolizumab. ( Prof Alex Eggermont - Paris-Sud University, Paris, France )

Clinical development and economic prospects of CAR T cell immunotherapies

Dr Bob Velamehr - Fate Therapeutics, La Jolla, USA

Clinical development and economic prospects of CAR T cell immunotherapies ( Dr Bob Velamehr - Fate Therapeutics, La Jolla, USA )

Theranostic imaging of lymphoma using radiolabelled αCD19-antibodies

Dr Dominik Sonanini - Tübingen University Hospital, Tübingen, Germany

Theranostic imaging of lymphoma using radiolabelled αCD19-antibodies ( Dr Dominik Sonanini - Tübingen University Hospital, Tübingen, Germany )

Response and safety profile of neoadjuvant nivolumab for resectable lung cancer

Dr Drew Pardoll - Johns Hopkins Medicine, Baltimore, USA

Doubled survival in metastatic lung cancer with combination therapy

Dr Leena Gandhi - NYU Langone Medical Center, New York, USA

Doubled survival in metastatic lung cancer with combination therapy ( Dr Leena Gandhi - NYU Langone Medical Center, New York, USA )

Combined immuno-chemotherapy improves survival and responses in metastatic lung cancer

Dr Leena Gandhi - NYU Langone Medical Center, New York, USA

Combined immuno-chemotherapy improves survival and responses in metastatic lung cancer ( Dr Leena Gandhi - NYU Langone Medical Center, New York, USA )

Results from CheckMate-227 : Immune combination reaches PFS endpoint

Dr Matthew Hellmann - Memorial Sloan Kettering Cancer Center, New York, USA

Results from CheckMate-227 : Immune combination reaches PFS endpoint ( Dr Matthew Hellmann - Memorial Sloan Kettering Cancer Center, New York, USA )

How the SBIR development centre funds cancer initiatives

Michael Weingarten - National Cancer Institute, Rockville, USA

How the SBIR development centre funds cancer initiatives ( Michael Weingarten - National Cancer Institute, Rockville, USA )

Supporting technological initiatives in low and middle income countries

Dr Paul Pearlman - National Cancer Institute, Rockville, USA

Supporting technological initiatives in low and middle income countries ( Dr Paul Pearlman - National Cancer Institute, Rockville, USA )

More from ecancer